MicroRNA-199a/b-5p inhibits endometrial cancer cell metastasis and invasion by targeting FAM83B in the epithelial-to-mesenchymal transition signaling pathway

HANZHEN XIONG1*, NA WANG1*, HUI CHEN1, MINFEN ZHANG1 and QIONGYAN LIN2

1Department of Pathology, Central Laboratory of The Third Affiliated Hospital of Guangzhou Medical University; 2Department of Gynecology and Obstetrics, Guangzhou Institute of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China

Received April 20, 2020; Accepted October 27, 2020

DOI: 10.3892/mmr.2021.11943

Abstract. Our previous study demonstrated the role of family with sequence similarity 83, member B (FAM83B) in endometrial cancer tumorigenesis and metastasis. FAM83B is involved in epithelial-to-mesenchymal transition (EMT). However, the regulatory network of EMT, which promotes endometrial cancer cell metastasis, involving microRNAs (miRNAs/miRs) and FAM83B, has not been elucidated. To investigate the potential mechanism underlying miR-199a/b-5p in endometrial cancer, the effect of miR-199a/b-5p and its targeted FAM83B gene on the biological behaviour of endometrial cancer cells was assessed. The Gene Expression Omnibus dataset analysis results revealed that the expression levels of 150 miRNAs in non-cancerous endometrial tissues were upregulated compared with those in endometrial cancer tissues. TargetScan predicted that the nucleotides 672-679 of FAM83B 3'‑untranslated region (UTR) were the target sites of miR-199a/b-5p. The differentially expressed miRNAs were enriched in several Kyoto Encyclopedia of Genes and Genomes pathways. Reverse transcription-quantitative PCR analysis revealed that the expression levels of miR-199a/b-5p in the endometrial non-cancerous cell lines were significantly upregulated compared with those in the six endometrial cancer cell lines. miR-199a/b-5p inhibited the EMT signaling pathway by regulating the expression levels of E-cadherin, N-cadherin, Snail, α-smooth muscle actin, vimentin and Twist. This suggested that miR-199a/b-5p inhibited endometrial cancer cell proliferation and migration through the inhibition of the EMT signaling pathway. Furthermore, the nucleotides 672-679 of the FAM83B 3'-UTR were demonstrated to be the binding site of miR-199a/b-5p. These results suggested that miR-199a/b-5p inhibited endometrial cancer cell proliferation and metastasis by targeting the 3'-UTR of FAM83B, which is involved in the EMT signaling pathway.

Introduction

Endometrial cancer is one of the most common gynecological cancers in China and is a major threat to women's health (1). The incidence and mortality rates of endometrial cancer in China are 8.56 and 1.94 per 100,000 individuals, respectively (2). Furthermore, patients diagnosed with late-stage endometrial cancer exhibit a poor prognosis (3). Thus, there is a need to elucidate the molecular mechanisms underlying endometrial cancer to develop reliable predictive biomarkers and effective therapeutic agents.

Epithelial-to-mesenchymal transition (EMT) is a phenotypic plasticity process that confers migratory and invasive properties to epithelial cells during the pathogenesis of endometrial cancer (4). EMT is mediated by cell adhesion molecules (E-cadherin and N-cadherin), transcription factors (Snail and Twist), α-smooth muscle actin (SMA) and vimentin (5). Additionally, various microRNAs (miRNAs/miRs) modulate the regulatory network of EMT. Drug resistance and prognosis in patients with various types of cancer, such as breast, colorectal, bladder, ovarian and endometrial cancer, are directly determined by EMT-associated factors (6,7). Previous
studies have demonstrated that EMT-associated factors, which are upregulated in cancer, mediate cancer cell proliferation, migration and invasion. For example, Padmanaban et al. (8) reported that E-cadherin promotes metastasis in multiple models of breast cancer, and Li et al. (9) demonstrated that Snail-induced claudin-11 promotes tumor progression by increasing cancer cell migration. Thus, EMT-associated factors serve vital roles in the tumorigenesis of endometrial cancer.

Family with sequence similarity 83, member B (FAM83B) is reported to be a novel molecule involved in the development of various malignant tumors, including pancreatic ductal adenocarcinoma (10) and gastric cancer (11). Previous studies have demonstrated that FAM83B can directly activate the PI3K/AKT/mTOR signaling pathway in tumors, including breast, lung, ovarian and cervical cancer, by binding to PI3K (12,13) or can indirectly activate the pathway by binding and hyper-activating EGFR in lung adenocarcinoma (14). Our previous study demonstrated that FAM83B knockdown inhibits endometrial cancer cell proliferation and metastasis through the inhibition of the PI3K/AKT/mTOR signaling pathway (15). Collectively, the aforementioned studies suggest that the pathogenesis of various types of cancer is mediated by FAM83B.

miR-199 is a highly conserved miRNA family that comprises miR-199a and miR-199b (16). A previous study demonstrated that miR-199a-5p inhibits the proliferation, migration and invasion of cancer cells (17). Additionally, miR-199a-5p activates EMT-associated signaling pathways (18). In endometrial carcinoma, the dysregulation of miR-199b in tissues and plasma results in the upregulation of the mTOR kinase (19). Previous studies have reported a one-to-one or one-to-two association of miR-199, FAM83B, EMT, cell metastasis and endometrial cancer. However, the role of miR-199-a/b-5p, which targets FAM83B, in endometrial cancer has not been elucidated (11,15,20–22).

In the present study, the target genes of miR-199-a/b-5p (including FAM83B) and the signaling pathways in which they are enriched were predicted through data mining. The expression levels of miR-199-a/b-5p, FAM83B, E-cadherin, N-cadherin, Snail, α-SMA, vimentin and Twist were examined in endometrial cancer cell lines. Additionally, the biological functions of miR-199-a/b-5p and FAM83B in the proliferation, migration, invasion, in vivo tumor formation and pulmonary metastasis of endometrial cancer cells were evaluated. Furthermore, the 3' untranslated region (UTR) binding sites of miR-199-a/b-5p in FAM83B was investigated.

Materials and methods

Gene Expression Omnibus (GEO) dataset analysis. Wang et al. (23) confirmed that GEO datasets can provide a more convenient way to screen gene expression between disease and non-disease cases, therefore GEO datasets were used to analyze the difference in miRNA expression between endometrial adenocarcinoma and non-cancerous tissues. Of the 48 samples in the dataset GSE25405_RAW.tar, the microarray data of 27 samples were downloaded from GEO of the National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/geo). The datasets were divided into the following groups: Seven non-cancerous endometrial tissue datasets (GSM623853-GSM623855 and GSM623875-GSM623878) and 20 endometrioid adenocarcinoma datasets (GSM623856-GSM623874 and GSM623881). The Agilent-019118 Human miRNA Microarray 2.0 G4470B (GPL7731) data were analyzed using the Agilent GeneSpringGX Software (version 11.5; Agilent Technologies, Inc.). The differentially expressed miRNAs were identified based on the following criteria: P<0.01 and log₂ fold change (FC) <−2. Heatmap and volcano plot were used to represent the differentially expressed miRNAs. To determine the expression in the microarray data, the differential gene expression profile data (GSE35794) of the top 250 miRNAs were analyzed using NCBI GEO2R (version R 3.2.3; https://www.ncbi.nlm.nih.gov/geo/geo2r/).

Target gene prediction. The putative miRNA targets were predicted using TargetScan 7.2 (www.targetscan.org/vert_72). Additionally, the poorly conserved 3'-UTR of FAM83B was predicted.

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The predicted target genes of miR-199-a/b-5p were annotated using Kobas (version 3.0; kobas.cbi.pku.edu.cn/kobas3). The KEGG pathway enrichment analysis was performed using R clusterProfiler (version 3.10.1; aipufu.com/index.html).

Cell culture and transfection. Human endometrial cancer cell lines (AN3 CA, HEC-1-B, RL95-2, HEC-1-A, Ishikawa) were purchased from the American Type Culture Collection, human endometrial epithelial cells (hEECs) were purchased from Procell Life Science & Technology Co., Ltd. (cat. no. CP-H058) and the JEC cell line was purchased from YRGene (cat. no. CC021). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, HyClone; Cytiva) supplemented with 10% fetal bovine serum (FBS; HyClone; Cytiva), 100 µg/ml streptomycin and 100 U/ml penicillin (Thermo Fisher Scientific, Inc.) at 37°C and 5% CO₂ conditions.

For transfection experiments, the six human endometrial cancer cell lines (2.5x10⁴) were seeded in a 6-well plate and incubated overnight at 37°C with 5% CO₂. Subsequently, cells were transfected with 100 nM miRNA mimics or inhibitors, 50 nM FAM83B small interfering (si)RNA or 50 nM FAM83B overexpression plasmid for 4 h. At 24 h post-transfection, cells were used for subsequent experiments. Sequences of siRNA and miRNA mimics/inhibitors, including the negative controls, were as follows: miR-199a-5p mimics, 5'-CCC AGUGUUCAGACACUGUCUUC-3'; miR-199b-5p mimics, 5'-CCCAUGUUUUAAGACUACUGUUCC-3'; miR-199a/b-5p mimics negative control, 5'-UCACACCUCCGUAGAGGA GAGA-3'; miR-199a-5p inhibitor, 5'-GAACAGGUAGUC UGAACACUGGG-3'; miR-199b-5p inhibitor, 5'-GAACAG GTAGTCAACACGTGGG-3'; and miR-199a/b-5p inhibitor negative control, 5'-CAGUACUUUUGUGUAGACAA-3'.

The miR-199a/b-5p mimics/inhibitor, si-FAM83B constructs, FAM83B overexpression plasmid (pcDNA3.1 vector) and their negative controls (scramble) were synthesized by Sangon Biotech Co., Ltd. To overexpress miR-199a/b-5p, the
cells were transfected with miR-199a-5p and miR-199b-5p mimics mixed in a ratio of 1:1. All RNA transfections were performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions.

Animal experiments. A total of 48 female BALB/c-nu/nuspecific pathogen-free mice from Guangdong Medical Laboratory Animal Center (6-weeks old; 13-15 g) were used in the present study. Mice were housed in a temperature-controlled room (at 24±1°C) with 50±10% humidity, 12-h light/dark cycles, and standard rodent food and water ad libitum in polystyrene cages. All animal experiments were approved by the Animal Care and Use Committee of Guangzhou Medical University (Guangzhou, China; approval no. GD2019-036) and conducted according to the National Institutes of Health guidelines (24).

Subcutaneous xenograft animal model and in vivo pulmonary metastasis assay. In each subgroup, mice were lively, and daily observation revealed no abnormality in eating or any marked weight loss. Following terminal anesthesia by intraperitoneal injection with pentobarbital sodium (100 mg/kg body weight), mice were euthanized by cervical dislocation and the death of the mice was verified according to the following criteria: i) no breathing; ii) no nerve reflexes; iii) no heartbeat; and iv) relaxed muscles. The normal lung and tumor tissues were quickly dissected. The maximum tumor diameter observed for a single subcutaneous tumor during the xenograft assay was 19.7 mm.

The miR-199a/b-5p agomir/antagomir and miRNA agomir/antagomir control (scramble) constructs were purchased from Guangzhou RiboBio Co., Ltd. To overexpress miR-199a/b-5p, cells were transfected with miR-199a-5p agomir and miR-199b-5p agomir mixed in a ratio of 1:1. The sequences of the agomirs were as follows: miR-199a-5p agomir, 5'-CCACAGUGUCCACCUAGUCGUC-3'; miR-199b-5p agomir, 5'-CCACAGUGUCCACCUAGUCGUC-3'; miR-199a/b-5p agomir negative control, 5'-GUCUCCGUCUGUCCAAUCUGAC-3'; and miR-199a-5p antagomir, 5'-GAACACGGUGACGUGACUGGGG-3'; miR-199b-5p antagomir, 5'-GAACAGGTAGTCTAACACCTGGG-3'; and miR-199a/b-5p antagomir negative control, 5'-UAAUAGGGCAGCAGGAAUCGGA-3'. Ishikawa and JEC cells were transfected with 50 nM miR-199a/b-5p agomir or 100 nM agomir at 37°C using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) for 4 h. At 24 h post-transfection, cells were used for subsequent experiments. Subsequently, cells were cultured in complete medium at 37°C with 5% CO₂. Transfected cells were harvested and reseeded in PBS. The resuspended cells (5x10⁶) were subcutaneously injected into the right flank of 6-week-old female BALB/c nu/nu mice. Three weeks later, the mice were euthanized and the tumors were excised. The tumor volume was calculated using the following equation: Volume = (length x width²)/2. To establish an in vivo pulmonary metastasis model, 100 µl suspension of cancer cells (1x10⁵) was injected into the tail vein of 6-week-old female BALB/c nu/nu mice. All mice were sacrificed at four weeks post-injection. Lung tissue was excised and fixed with 10% formalin for 48 h at 25°C, paraffin-embedded and sectioned into 4-µm-thick sections. At room temperature, sections were stained with hematoxylin for 4 min followed by staining with eosin for 90 sec. Stained sections were observed using a light microscope (Olympus Corporation; magnification, x200).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from Ishikawa and JEC cell lines, as well as the lung tissues of laboratory mice using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The extracted RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Biotechnology Co., Ltd.), following the manufacturer's instructions. The RT-qPCR analysis was performed using the SYBR Premix ExTaq II kit (Takara Biotechnology Co., Ltd.), according to the manufacturer's protocol, using a 7500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR conditions were as follows: 95°C for 5 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The primers used for RT-qPCR analysis were as follows: miR-199a-5p and miR-199b-5p forward, 5'-ACACTCAGCTGGGC CCAGTGTCCAGACTAC-3' and reverse, 5'-CTCACTGG TGTCGTGGA-3'; U6 forward, 5'-CTCGCTTGGCCAGCA CA-3' and reverse, 5'-AAGCGCTTCGAAATTTGCAGT-3'; FAM3B forward, 5'-AAAGCTCACTCATGACTGGT-3' and reverse, 5'-AGCAATGATCAGTGGAGC-3'; and GAPDH forward, 5'-GGCTATTGGCAGGGGGGAG-3' and reverse, 5'-GGTGTTGGTGCCAGGGAGCA-3'. The levels of target RNA were normalized to those of U6 or GAPDH. The relative miR-199a/b-5p and FAM3B expression levels were calculated using the 2-ΔΔCq method (25). All PCR experiments were performed in triplicate.

Western blotting. The harvested cells were lysed with ice-cold SDS lysis buffer (Beyotime Institute of Biotechnology). The protein concentration in the lysate was determined using a BCA protein assay kit (Nanjing KeyGen Biotech Co., Ltd.), following the manufacturer's instructions. Equal amounts of denatured proteins (20 µg/lane) were separated via 10% SDS-PAGE and transferred to a polyvinylidene fluoride membrane (EMD Millipore). The membrane was blocked with 5% BSA (Beijing Solarbio Science & Technology Co., Ltd.) and incubated with primary antibodies at 4°C overnight. Next, the membrane was incubated with HRP-conjugated goat anti-rabbit (1:10,000; cat. no. ab205718; Abcam) secondary antibodies for 2 h at 25°C. The protein bands were visualized using ECL Western Blotting Substrate (Thermo Fisher Scientific, Inc.) and examined using the BIS 303 PC imaging system (DNR Bio-Imaging Systems Ltd.). GAPDH was used as a loading control. Protein expression levels were semi-quantified using ImageJ software (version 1.52n; National Institutes of Health). Primary antibodies against FAM3B (1:500; cat. no. PA5-28548; Invitrogen; Thermo Fisher Scientific, Inc.), E-Cadherin (1:5,000; cat. no. ab40772; Abcam), N-Cadherin (1 µg/ml; cat. no. ab18203; Abcam), Snail (0.3 µg/ml; cat. no. ab53519; Abcam), α-SMA (0.5 µg/ml; cat. no. ab5694; Abcam), vimentin (1:1,000; cat. no. ab92547; Abcam), Twist (2.5 µg/ml; cat. no. ab49254; Abcam) and GAPDH (1:10,000; cat. no. ab181602; Abcam) were used.
Transwell migration and invasion assay. Cell migration and invasion assays were performed using 24-well Transwell chambers (BD Biosciences). For the invasion assay, the Transwell chambers were precoated with Matrigel® (BD Biosciences) for 6 h at 37°C. The harvested cells (1x10⁴) were placed in the top chamber containing serum-free medium at 37°C with 5% CO₂. The bottom chamber contained complete medium supplemented with 10% FBS. The cells were incubated at 37°C and 5% CO₂ for 48 h. The migrated and invaded cells on the reverse side of the chamber inserts were fixed with methanol for 30 min and stained with 0.1% crystal violet for 15 min at room temperature. The number of cells was measured in three randomly selected high-power fields across the center and the periphery of the membrane using a light microscope (Olympus Corporation; magnification, x200). All experiments were performed in triplicates.

Dual-Luciferase reporter assay. The amplified 3'-UTR fragments of FAM83B were cloned into the psi-CHECK-2 luciferase miRNA expression reporter vector (Promega Corporation). The 293T cells (2x10⁴; cat. no. CRL-11268; ATCC) were cultured in 24-well plates with DMEM (HyClone; Cytiva) supplemented with 10% FBS. Subsequently, cells were transfected with 50 nM miR-199a/b-5p mimics, 100 nM miR-199a/b-5p inhibitor or mimic negative control (NC), 0.5 µg of psi-CHECK-2 luciferase reporter vector containing the wild-type (WT) or mutant (Mut) 3'-UTR sequences of FAM83B, or empty vector. Transfections were performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. At 48 h post-transfection, the luciferase activity was assessed using the Dual-Luciferase Reporter Assay System (GloMax; Promega). Firefly luciferase activities were normalized to Renilla luciferase activities. Three independent experiments were performed in duplicates.

Statistical analysis. Data are presented as the mean ± standard deviation. Multiple comparisons were performed using one-way ANOVA followed by Dunnett's post-hoc test. All statistical analyses were performed using SPSS (version 19.0; IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

miR-199a/b-5p expression is downregulated in patients with endometrial cancer. The cluster analysis of the GSE25405 dataset revealed 150 differentially expressed miRNAs between the non-cancerous endometrial tissues and human endometrial cancer tissues (Fig. 1A and B). Based on the criteria of P<0.01 and log2 FC >2, 24 miRNAs were screened out with significantly different expression. Our previous study confirmed that upregulated FAM83B expression in endometrial cancer can affect the proliferation and metastasis of cancer cells (15). Therefore, FAM83B was chosen for further analysis. According to TargetScan 7.2 analysis, 4/24 significantly differentially expressed miRNAs (Fig. 1B) had binding sites with FAM83B. Therefore, miR-199a-5p and miR-199b-5p were chosen for further analysis. The KEGG pathway enrichment analysis revealed that the target genes of miR-199a/b-5p were enriched in several EMT-associated pathways, including TGF-β and mTOR (Fig. 1C).

miR-199a/b-5p expression is downregulated in human endometrial cancer cell lines. The expression levels of miR-199a/b-5p were examined in different endometrial cancer cells. RT-qPCR analysis revealed that the expression levels of miR-199a/b-5p were significantly downregulated in all six endometrial cancer cell lines (AN3 CA, HEC-1-B, RL95-2, HEC-1-A, Ishikawa and JEC) compared with those in the hEECs (Fig. 1D). The JEC and Ishikawa cell lines were chosen for further analysis as they exhibited the lowest expression levels of miR-199a/b-5p. Additionally, the RT-qPCR analysis revealed that compared with the respective negative control, the expression levels of miR-199a/b-5p in Ishikawa and JEC cells were significantly upregulated after transfection with miR-199a-5p and miR-199b-5p mimics, and significantly downregulated after transfection with miR-199a-5p and miR-199b-5p inhibitors (Fig. 1E), which indicated that the miR-199a-5p and miR-199b-5p mimics and inhibitors were effective. Transfection with si-FAM83B knocked down FAM83B with an efficiency of >80% in both Ishikawa and JEC cells (Fig. 1F). Compared with the mimic NC-transfected group, the FAM83B mimic-transfected group exhibited significantly increased FAM83B expression (Fig. 1F), which indicated that the overexpression of FAM83B was effective.

miR-199a/b-5p inhibits the migration and invasion of JEC and Ishikawa cells. The Ishikawa and JEC cells were transfected with miR-199a/b-5p mimics to examine the effect of miR-199a/b-5p on the migration and invasion of cancer cells. The results of the Transwell assay revealed that the migratory and invasive abilities of the miR-199a/b-5p mimic-transfected cells at 48 h post-transfection were significantly lower compared with those of the mimic NC-transfected cells (Fig. 2).

miR-199a/b-5p inhibits the EMT signaling pathway in Ishikawa and JEC cells. The signaling pathway through which miR-199a/b-5p mediates cell migration and invasion in the Ishikawa and JEC cells was investigated. Western blot analysis revealed that the protein expression levels of FAM83B, N-cadherin, Snail, α-SMA, vimentin and Twist in the miR-199a/b-5p mimic-transfected Ishikawa and JEC cells were significantly lower compared with those in the mimic NC-transfected Ishikawa and JEC cells at 48 h post-transfection. By contrast, transfection with the miR-199a/b-5p mimics significantly upregulated the expression levels of E-cadherin compared with those of the mimic NC-transfected Ishikawa and JEC cells (Fig. 3A). These findings suggested that miR-199a/b-5p inhibited the EMT signaling pathway in Ishikawa and JEC cells.

FAM83B attenuates the miR-199a/b-5p-induced EMT signaling pathway inhibition in Ishikawa and JEC cells. The expression levels of N-cadherin, Snail, α-SMA, vimentin and Twist were evaluated in the FAM83B mimic-transfected Ishikawa and JEC cells at 48 h post-transfection. Transfection with the FAM83B mimic significantly attenuated the
miR-199a/b-5p mimic-induced downregulation of the expression levels of N-cadherin, Snail, α-SMA, vimentin and Twist in the Ishikawa and JEC cells (Fig. 3B). Additionally, transfection with FAM83B mimics significantly downregulated the expression levels of E-cadherin compared with those of mimic NC-transfected Ishikawa and JEC cells (Fig. 3B). These findings suggested that FAM83B may activate the EMT signaling pathway in Ishikawa and JEC cells.

**FAM83B attenuates the miR-199a/b-5p-induced inhibition of the migratory and invasive abilities of Ishikawa and JEC cells.** To evaluate the effects of activating the EMT signaling pathway on cancer cell migration and invasion, Ishikawa and JEC cells were further transfected with FAM83B mimics for 48 h. Compared with the miR-199a/b-5p mimic-transfected Ishikawa and JEC cells, FAM83B mimic-transfected Ishikawa and JEC cells exhibited significantly higher
migratory and invasive abilities (Fig. 4A). Additionally, the effects of miR-199a/b-5p inhibitors and FM83B knockdown on the migration and invasion of Ishikawa and JEC cells were examined. Transfection with miR-199a/b-5p inhibitors significantly enhanced the migration and invasion of Ishikawa and JEC cells compared with those of inhibitor NC-transfected Ishikawa and JEC cells (Fig. 4B). By contrast, transfection with si-FAM83B significantly attenuated the miR-199a/b-5p inhibitor-induced migration and invasion of Ishikawa and JEC cells (Fig. 4C). These findings indicated that FM83B attenuated the miR-199a/b-5p-induced inhibition of the migration and invasion of Ishikawa and JEC cells.

miR-199a/b-5p regulates metastasis. The role of miR-199a/b-5p in regulating metastasis of endometrial cancer cells was examined using the BALB/c nu/nu mouse
subcutaneous tumor and pulmonary metastasis models. The administration of miR-199a/b-5p agomir-transfected cancer cells significantly inhibited the growth of subcutaneous tumors in the nude mice compared with that of the agomir NC-transfected group (Fig. 5A and B). By contrast, the administration of miR-199a/b-5p antagomir-transfected cancer cells significantly enhanced the growth of subcutaneous tumors compared with that of the antagomir NC-transfected group (Fig. 5A and B). These findings suggested that miR-199a/b-5p inhibited the growth of endometrial cancer cells in vivo.

Meanwhile, miR-199a/b-5p expression levels in tumors were also analyzed via RT-qPCR. The results confirmed successful transfection of miR-199a/b-5p agomir and antagomir in subcutaneous tumors. (Fig. 5C). Additionally, a pulmonary metastasis model was established by injecting the cancer cells through the tail vein. Compared with the respective control groups, miR-199a/b-5p agomir significantly inhibited the lung metastasis and tumor nodules, whereas miR-199a/b-5p antagomir significantly enhanced lung metastasis and tumor nodules. (Fig. 5D-F).

**FAM83B is a direct target of miR-199a/b-5p.** The functions of miR-199a/b-5p in endometrial cancer cell was validated using FAM83B as a target. Single putative miR-199a/b-5p recognition site was predicted within the FAM83B 3'-UTR sequences. FAM83B contained a 7-nucleotide site within its 3'-UTR, which matched with the seed region of miR-199a/b-5p (Fig. 6A).

The mechanism through which miR-199a/b-5p modulates FAM83B expression was examined by introducing the 3'-UTR of FAM83B containing one miR-199a/b-5p binding site downstream of a luciferase reporter. The luciferase activity of WT FAM83B 3'-UTR construct in cells transfected with miR-199a/b-5p mimics was significantly lower compared with that in cells transfected with the mimic NC (Fig. 6B). A luciferase reporter containing the Mut FAM83B 3'-UTR binding site of miR-199a/b-5p was also constructed. The luciferase activity of the Mut FAM83B 3'-UTR construct was not suppressed upon transfection with miR-199a/b-5p mimics or inhibitor (Fig. 6B). This indicated that miR-199a/b-5p may bind selectively to mRNAs and that
the single recognition element identified in the 3'-UTR of the FAM83B mRNA may be sufficient for miR-199a/b-5p activity. These results indicated that miR-199a/b-5p directly targeted FAM83B.

Discussion

Globally, the incidence and mortality rates of endometrial cancer, which is one of the most common malignancies among women, have increased (26). Previous studies have suggested that various abnormally expressed miRNAs are potential predictive biomarkers for the diagnosis or prognosis of endometrial cancer (27,28). However, the molecular mechanisms underlying the pathogenesis of endometrial cancer have not been elucidated. In the present study, miR-199a/b-5p expression was downregulated in human endometrial cancer cells compared with in hEECs. Additionally, miR-199a/b-5p inhibited the migration and invasion of the endometrial cancer cells through the suppression of EMT-associated factors and EMT signaling pathway. However, FAM83B attenuated the miR-199a/b-5p-induced inhibition of cancer cell migration and invasion through the activation of the EMT signaling pathway. Additionally, miR-199a/b-5p was bound to the nucleotides 672-679 of the FAM83B 3'-UTR.

Our previous study demonstrated that the upregulated FAM83B expression is associated with decreased survival in patients with endometrial cancer (15). Grant (29) demonstrated that FAM83B is a candidate oncogene that mediates...
The present study had a number of limitations. First, the in vitro regulatory mechanism underlying miR-199a/b-5p-mediated FAM83B expression was not investigated in the present study, although KEGG enrichment studies were performed. Additionally, the effects of other hypothesized target genes that were predicted to bind to miR-199a/b-5p in endometrial cancer cells were not investigated. Therefore, further investigations are acquired.

In conclusion, the present study demonstrated that miR-199a/b-5p was downregulated in endometrial cancer and that FAM83B promoted cancer cell metastasis and invasion by activating the EMT signaling pathway. Additionally, miR-199a/b-5p was demonstrated to bind to the nucleotides 672-679 of the FAM83B 3'-UTR. The current findings may improve the understanding of the role of FAM83B in endometrial cancer. Furthermore, the present study indicated that FAM83B may be a potential therapeutic target for endometrial cancer. The elucidation of the role of miR-199a/b-5p and FAM83B in EMT will aid in improving diagnosis and developing therapeutic agents for endometrial cancer, as well as evaluating drug efficacy and prognosis in patients with endometrial cancer. The role of miRNAs and FAM83B in endometrial cancer should be evaluated using an independent large population in future studies.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Guangzhou Medical University PhD Start Fund (grant no. 2016C22), Guangzhou Medical University PhD Start Fund (grant no. 2016C24), Guangzhou Medical University Affiliated Third Hospital Elite Talent Program Initiation Fund.

Availability of data and materials

The datasets generated and/or analyzed during the current study (GSE25405 and GSE35794) are available in the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) repository. All other data are available from the corresponding author on reasonable request.

Authors' contributions

HX, NW and QL conceived and designed the study and performed the experiments and collected the data. HX, NW and QL performed the experiments and collected the data. HX and NW drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures involving mice and the corresponding experimental protocols were approved by the Animal Care and Use Committee of Guangzhou Medical University (Guangzhou, China; approval no. GD2019-036).
The authors declare that they have no competing interests.

References

1. Morice P, Leary A, Creutzberg C, Abu‐Rustum N and Darai E: Endometrial cancer. Lancet 387: 1094‐1108, 2016.
2. Geng YH, Wang ZF, Jia Y, Cheng LY, Chen L, Liu YJ, Li XH, Tian XX and Fang WG: Genetic polymorphisms in CDH1 are associated with endometrial carcinoma susceptibility among Chinese Han women. Oncol Lett 16: 6686‐6687, 2018.
3. Rodriguez AM, Schmeler KM and Kuo YF: Lack of improvement in survival rates for women under 50 with endometrial cancer, 2000–2011. J Cancer Res Clin Oncol 142: 783‐793, 2016.
4. Zhang HH, Li R, Li YJ, Yu XX, Sun QN, Li AY and Kong Y: c‐HPR‐related miR‐20a and miR‐340p inhibit endometrial carcinoma cell metastatic capability by preventing TGF‐β1‐induced epithelial‐mesenchymal transition. Oncol Rep 43: 447‐450, 2020.
5. Su J, Morgani SM, David CJ, Wang Q, Er EE, Huang YH, Basnet H, Zhou Y, Shen X, Soni RK, et al.: TGF‐beta orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature 577: 566‐571, 2020.
6. Qureshi R, Arora H and Rizvi MA: EMT in cervical cancer: Its role in tumour progression and response to therapy. Cancer Lett 356: 321‐331, 2015.
7. Mutlu M, Raza U, Saatci O, Yeyupolu E, Yurdusev E and Sahin O: miR‐200c: A versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med (Berl) 94: 629‐644, 2016.
8. Padmanabhan V, Krol I, Suhaili Y, Szczepura BM, Aceto N, Bader JS and Ewals KE: Er‐adherin is required for metastasis in multiple models of breast cancer. Nature 573: 439‐444, 2019.
9. Li CF, Chen JY, Ho YH, Hu WH, Lu LC, Han SY, Hu D, Niu SF, Tai SK, Chang YC and Yang MH: Snail1‐induced epithelial‐mesenchymal transition. Oncol Rep 36: 1181‐1187, 2016.
10. Shen CQ, Yan TT, Liu W, Zhu QX, Tian XL, Fu XL, Hua R, Zhang JF, Hu YM, Liu DJ, et al.: High expression of FAM83B predicts poor prognosis in patients with pancreatic ductal adenocarcinoma and correlates with cell cycle and cell proliferation. J Cancer 8: 3154‐3165, 2017.
11. Zou Z, Ma T, He X, Zhou J, Ma H, Xie M, Liu Y, Lu D, Si Z and Zhang L: Long intergenic non‐coding RNA 00324 promotes endometrial cancer cell proliferation via binding with HuR and eIF4E. Oncol Rep 32: 1241‐1250, 2015.
12. Cipriano R, Graham J, Miskimen KL, Bryon BL, Bruntz RC, Scott SA, Brown HA, Stark GR and Jackson MW: FAM83B mediated EGFR‐ and RAS‐driven oncogenic transformation. J Clin Invest 122: 3197‐3210, 2012.
13. Cipriano R, Miskimen KL, Bryon BL, Foy CR, Bartel CA and Jackson MW: FAM83B‐mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget 7: 729‐738, 2016.
14. Yamaura T, Etsuki J, Okabe N, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Fukushima M, Muto S, Matsumura Y, et al.: Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild‐type epidermal growth factor receptor. Oncol Lett 15: 1549‐1558, 2018.
15. Lin Q, Chen H, Zhang M, Xing H and Jiang Q: Knockdown of FAM83B inhibits endometrial cancer cell proliferation by silencing the PI3K/AKT/mTOR pathway. Biomed Pharmacother 115: 108939, 2019.
16. Wang Q, Ye B, Wang P, Yao F, Zhang C and Yu G: Overview of microRNA‐199a Regulation in Cancer. Cancer Manag Res 11: 10327‐10335, 2019.
17. Ye H, Pang Y, Liu L, Wu Q, Zhu Y, Guo C, Deng Y and Zheng X: A critical role of mir‐199a in the cell biological behaviors of colorectal cancer. Diagn Pathol 10: 65, 2015.